About

Aziza Ahmed is a Professor of Law whose scholarship examines the intersection of law, politics, and science across various fields including constitutional law, criminal law, health law, and family law. Prior to her current position at Boston University School of Law, she was a professor of law at the University of California, Irvine School of Law and has also taught at Northeastern University School of Law. Her work focuses on analyzing how legal frameworks interact with scientific and political issues, contributing to academic discussions and policy debates in these areas.

Research topics

• Immunology
• Medicine
• Internal medicine
• Dermatology
• Intensive care medicine
• Surgery
• Gastroenterology

Selected publications

• Use of rituximab in the treatment of mucous membrane pemphigoid: An analytic review

  Autoimmunity Reviews · 2022 · 9 citations

  Senior authorCorresponding
  • Medicine
  • Internal medicine
  • Gastroenterology
  DOI

• The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review

  Expert Opinion on Biological Therapy · 2021 · 11 citations

  Senior authorCorresponding
  • Medicine
  • Immunology
  • Intensive care medicine

  INTRODUCTION: Pemphigus vulgaris (PV) is a life-threatening autoimmune mucocutaneous blistering disease. Systemic corticosteroids (CS), while life-saving, have several serious side effects. To improve treatment and prognosis, recently rituximab (RTX), a chimeric monoclonal antibody against CD20 molecule on B cells, has become popular. This Expert Opinion discusses clinical and scientifically relevant aspects of RTX treating PV. AREA COVERED: This presentation describes the mechanism of action, clinical efficacy, safety, adverse events, protocols used, and clinical outcomes. Concerns for infection, reactivation of latent or previous infections, and high relapse rate are discussed. EXPERT OPINION: Use of RTX in PV is still a work in progress. There are many unanswered questions. FDA did not provide a protocol or guidelines. Whenever RTX is used, systemic corticosteroids are simultaneously used, albeit for a shorter duration and lower dose. Used in these doses for these durations they can cause immunosuppression. Would it be more appropriate if instead of 'First Line Therapy' it would be more advisable to use the term 'First Adjunctive Immunosuppressive Agent'?

  DOI

• Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia

  Autoimmunity Reviews · 2020 · 81 citations

  Senior authorCorresponding
  • Immunology
  • Medicine
  DOI

Recent grants

• NIH Grant R01DE009978

  NIH · $1.1M · 1997

• NIH Grant R01EY014228

  NIH · $739k · 2007

• NIH Grant R01EY008379

  NIH · $2.9M · 2003

Frequent coauthors

• C. Stephen Foster

  Harvard University

  36 shared

• Kailash C. Bhol

  Acetylon Pharmaceuticals (United States)

  36 shared

• Naveed Sami

  Florida College

  31 shared

• Hakan M. Gürcan

  21 shared

• Mikole Kalesinskas

  Tufts University

  19 shared

• Caden Carver

  Midwestern University

  17 shared

• Roy S. Rogers

  Mayo Clinic in Florida

  17 shared

• Ngawang Dheden

  Queen Mary University of London

  16 shared

Labs

• International Human Rights ClinicPI

Similar researchers at Boston University

• Alexa S. Beiserh-188
• David Boash-156
• Benjamin Sovacoolh-143
• Kathryn L. Lunettah-132
• Ranga Mynenih-130